300702 Stock Overview
Engages in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Zhejiang Tianyu Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥17.42 |
| 52 Week High | CN¥22.22 |
| 52 Week Low | CN¥13.16 |
| Beta | -0.0092 |
| 1 Month Change | 1.57% |
| 3 Month Change | 24.96% |
| 1 Year Change | -20.60% |
| 3 Year Change | -62.48% |
| 5 Year Change | -42.10% |
| Change since IPO | 44.95% |
Recent News & Updates
Zhejiang Tianyu Pharmaceutical Co., Ltd.'s (SZSE:300702) Price Is Right But Growth Is Lacking
Dec 03
We Think Zhejiang Tianyu Pharmaceutical (SZSE:300702) Is Taking Some Risk With Its Debt
Nov 04Concerns Surrounding Zhejiang Tianyu Pharmaceutical's (SZSE:300702) Performance
Sep 04Recent updates
Zhejiang Tianyu Pharmaceutical Co., Ltd.'s (SZSE:300702) Price Is Right But Growth Is Lacking
Dec 03We Think Zhejiang Tianyu Pharmaceutical (SZSE:300702) Is Taking Some Risk With Its Debt
Nov 04Concerns Surrounding Zhejiang Tianyu Pharmaceutical's (SZSE:300702) Performance
Sep 04Take Care Before Diving Into The Deep End On Zhejiang Tianyu Pharmaceutical Co., Ltd. (SZSE:300702)
Aug 21Further Upside For Zhejiang Tianyu Pharmaceutical Co., Ltd. (SZSE:300702) Shares Could Introduce Price Risks After 27% Bounce
May 21Zhejiang Tianyu Pharmaceutical Co., Ltd.'s (SZSE:300702) Revenues Are Not Doing Enough For Some Investors
Mar 17Shareholder Returns
| 300702 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -5.0% | -4.3% | -3.5% |
| 1Y | -20.6% | -3.4% | 10.9% |
Return vs Industry: 300702 underperformed the CN Pharmaceuticals industry which returned -3.4% over the past year.
Return vs Market: 300702 underperformed the CN Market which returned 10.9% over the past year.
Price Volatility
| 300702 volatility | |
|---|---|
| 300702 Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300702 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300702's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 4,690 | Yong Jun Tu | www.tianyupharm.com |
Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs in China and internationally. The company offers pharmaceutical intermediates and APIs of cardiovascular, anti-diabetic, anti-atherosclerosis, anticoagulant, and anti-asthmatic series. It provides fine chemicals and CDMO services.
Zhejiang Tianyu Pharmaceutical Co., Ltd. Fundamentals Summary
| 300702 fundamental statistics | |
|---|---|
| Market cap | CN¥5.99b |
| Earnings (TTM) | CN¥43.68m |
| Revenue (TTM) | CN¥2.59b |
137.2x
P/E Ratio2.3x
P/S RatioIs 300702 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300702 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.59b |
| Cost of Revenue | CN¥1.75b |
| Gross Profit | CN¥846.19m |
| Other Expenses | CN¥802.51m |
| Earnings | CN¥43.68m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 32.61% |
| Net Profit Margin | 1.68% |
| Debt/Equity Ratio | 47.6% |
How did 300702 perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield40%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 01:20 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Tianyu Pharmaceutical Co., Ltd. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kai Wang | Citic Securities Co., Ltd. |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| Wei Liu | Haitong International Research Limited |